title: [Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema].
abstract: OBJECTIVE
  To determine whether intravitreal injection of plasmin is effective in treating diffuse diabetic macular edema (DDME).
  
  
  METHODS
  A prospective, comparative, interventional case study.
  
  
  METHODS
  Eighteen patients with bilateral DDME received, as their primary therapeutic treatment, an intravitreal injection of plasmin in one eye, with their contralateral untreated eye serving as a control.
  
  
  METHODS
  Intravitreal 0.2 ml of autologous plasmin injected under topical anesthesia. The plasmin was obtained by a simplified method.
  
  
  METHODS
  Central macular thickness (CMT), determined by optical coherence tomography (OCT), and Best Corrected Visual Acuity (LogMAR), assessed at one and three months of follow-up.
  
  
  RESULTS
  All patients completed the 3-month follow-up assessments. Before the injection, the CMT was 525.22 SD 80.12 microm [mean +/- standard deviation (SD)] in the eyes to be injected, compared to 525.44 SD 78.13 microm in the control eyes. One month after the injection, the CMT was 323.72 SD 44.87 microm in the injected eyes and 518.44 SD 78.54 microm in the control eyes (P < 0.001, bilateral Wilcoxon test for paired samples). Three months after the injection, the CMT was 310.55 SD 35.38 microm in the injected eyes and 517.66 SD 80 microm in the control eyes (P < 0.001). Macular edema improved in all injected eyes (100%), with a reduction of at least 50% in every treated eye, but no changes occurred in the control group. Nine of the 18 treated eyes (50%) improved their BCVA by at least two vision lines. No adverse effects were observed in any of the patients.
  
  
  CONCLUSIONS
  Intravitreal plasmin injection, as primary treatment, effectively reduces macular thickening due to DDME and improves visual acuity. Further studies are warranted to assess long-term efficacy and safety.
authors.affiliation: Departamento de Oftalmología, Hospital Geneneral Universitario, Unidad Docente de Oftalmología, Facultad de Medicina, Universidad de Valencia, Valencia, España. manuel.diaz@uv.es
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Llopis
authors.forename: P
authors.initials: P
authors.lastname: Udaondo
authors.forename: S
authors.initials: S
authors.lastname: García-Delpech
authors.forename: E
authors.initials: E
authors.lastname: Cervera
authors.forename: D
authors.initials: D
authors.lastname: Salom
authors.forename: A
authors.initials: A
authors.lastname: Quijada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005260:Female; D005341:Fibrinolysin / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D014821:Vitrectomy / Q000379:methods*; D014822:Vitreous Body
chemical_list: D005341:Fibrinolysin